BioAtla, Inc. (BCAB) Prices 10.5M Share IPO at $18/Sh

BioAtla, Inc. (NASDAQ: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the pricing of its initial public offering of 10,500,000 shares of common stock at a public offering price of $18.00 per share. All of the shares of common stock are being offered by BioAtla. The shares of common stock are expected to begin trading on the Nasdaq Global Market on December 16, 2020 under the ticker symbol "BCAB." The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by BioAtla, are expected to be approximately $189.0 million. The offering is expected to close on December 18, 2020, subject to the satisfaction of customary closing conditions. In addition, BioAtla has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

J.P. Morgan, Jefferies and Credit Suisse are acting as joint book-running managers for the offering.

Registration statements relating to these securities became effective on December 15, 2020.

You May Also Be Interested In

• OpenAI revenue chief quits after less than a year
• Silence Therapeutics closes $201M public offering of ADSs
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating